Moreover, our laboratory has shown that aromatase inhibitors such as Formestane can rely on ER-independent but androgen receptor-dependent roles to suppress ER + breast cancer, suggesting that aromatase inhibitors may be highly recommended as promising agents combined with targeting the Hippo pathway to significantly overcome endocrine resistance stimulated by estrogen-deprivation therapy in postmenopausal women [157]. This evidence concerns the gene AR and breast carcinoma.